This 90-minute, three-part generative AI series helped me learn how to use artificial intelligence for work and everyday life. Here's what I learned.

The right data foundation isn’t just a technical requirement—it’s a competitive advantage. Companies that get it right will position themselves to win in the age of AI.

Wedbush analyst Dan Ives remains bullish and expects Tesla's market cap to hit $2 trillion in 2025, saying the coming four years will be a "total game changer" for Tesla. He expects the Trump administration to fast-track full self-driving (FSD), paving the way for the company's robotaxi agenda.

Spotify, a digital music streaming service, has developed an AI-powered robot DJ aimed to help listeners find their musical sweet spots without the hassle of wading through unknown, and possibly crappy,

Indeed, Musk suggested that synthetic data — data generated by AI models themselves — is the path forward. “The only way to supplement [real-world data] is with synthetic data, where the AI creates [training data],” he said. “With synthetic data … [AI] will sort of grade itself and go through this process of self-learning.”

From AI-driven defense to evolving ransomware tactics, here's what cybersecurity industry leaders and experts are preparing for this year.

A 'binary big bang' occurred when AI foundation models cracked the natural language barrier, kickstarting a shift in our technology systems: how we design them, use them, and how they operate.

Generative AI projects will move from pilot phase to production for many companies this year, which means the workforce will be affected in ways never before imagined, says Sarah Hoffman, director of AI research at AlphaSense.

It was almost a year before a handful of Chinese AI chatbots received government approval for public release. Some questioned whether China’s stance on censorship might hobble the country’s AI ambitions.

An AI expert argues AI progress hasn’t stalled, it’s become invisible, which could leave us unprepared for the future.

Over a video call, Alex Zhavoronkov holds up a small, green, diamond-shaped pill. It has been developed by his company to treat a rare progressive lung disease for which there is no known cause or cure. The new drug has yet to be approved, but in small clinical trials has shown impressive efficacy in treating idiopathic pulmonary fibrosis (IPF).

A study published today in the journal Nature by researchers at Columbia University described a new medical AI model that they say can accurately predict the activity of genes at the cellular level. In theory,